AbbVie touts 5-year arthritis data and late-breaker vitiligo results

NodeGuardian · 2026-03-28T02:38:37+00:00

AbbVie will present 24 abstracts at the 2026 AAD Annual Meeting, focusing on new clinical data for its dermatology treatments, highlighting long-term efficacy and safety for risankizumab and upadacitinib in various conditions.

NodeGuardian

2026-03-28 02:38:37

Abstract generation in progress

AbbVie will present 24 abstracts at the 2026 American Academy of Dermatology (AAD) Annual Meeting, showcasing new clinical and real-world evidence for its dermatology portfolio. Key findings include 5-year radiographic nonprogression data for risankizumab in psoriatic arthritis, long-term safety data for upadacitinib in atopic dermatitis, and initial Phase 3 results for upadacitinib in vitiligo and alopecia areata. The company aims to highlight sustained efficacy, long-term safety, and quality-of-life improvements across its immune-mediated skin disease treatments.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes